Takeda Pharmaceutical (NYSE:TAK) Sets New 52-Week High – Here’s Why

Takeda Pharmaceutical Co. (NYSE:TAK)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $18.82 and last traded at $18.7950, with a volume of 2001096 shares changing hands. The stock had previously closed at $18.66.

Analysts Set New Price Targets

TAK has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Morgan Stanley began coverage on Takeda Pharmaceutical in a research note on Tuesday, January 13th. They set an “overweight” rating for the company. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Saturday, January 31st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold”.

Takeda Pharmaceutical Stock Performance

The stock has a fifty day moving average of $16.62 and a 200-day moving average of $15.24. The firm has a market capitalization of $59.81 billion, a P/E ratio of 78.32 and a beta of 0.02. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, January 29th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.55 by $0.40. The firm had revenue of $6.75 billion for the quarter, compared to analysts’ expectations of $7.81 billion. Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%. On average, research analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TAK. Arrowstreet Capital Limited Partnership lifted its position in Takeda Pharmaceutical by 100.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after buying an additional 2,854,069 shares in the last quarter. UBS Group AG grew its holdings in shares of Takeda Pharmaceutical by 46.4% in the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after acquiring an additional 1,869,323 shares in the last quarter. Qube Research & Technologies Ltd increased its position in shares of Takeda Pharmaceutical by 407.9% in the third quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock valued at $25,998,000 after acquiring an additional 1,426,184 shares during the last quarter. Van ECK Associates Corp raised its holdings in Takeda Pharmaceutical by 98.4% during the fourth quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock worth $35,941,000 after acquiring an additional 1,143,117 shares in the last quarter. Finally, Voloridge Investment Management LLC boosted its position in Takeda Pharmaceutical by 1,070.7% during the fourth quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after purchasing an additional 880,289 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.